Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent two ends of a disease spectrum with shared clinical, genetic and pathological features. These include near ubiquitous pathological inclusions of the RNA binding protein (RBP) TDP-43, and often the presence of a GGGGCC expansion in the C9ORF72 (C9) gene. Previously we reported that the sequestration of hnRNP H altered the splicing of target transcripts in C9ALS patients (Conlon et al. 2016). Here we show that this signature also occurs in half of 50 post-mortem sporadic, non-C9 ALS/FTD brains. Furthermore, and equally surprisingly, these 'like-C9' brains also contained correspondingly high amounts of insoluble TDP-43, as well as several other disease-related RBPs, and this correlates with widespread global splicing defects. Finally, we show that the like-C9 sporadic patients, like actual C9ALS patients, were much more likely to have developed FTD. We propose that these unexpected links between C9 and sporadic ALS/FTD define a common mechanism in this disease spectrum.

Data availability

All raw RNASeq data from Target ALS samples is immediately made publicly available. Access to the data can be requested by emailing ALSData@nygenome.org.All RNASeq data from the ALS Consortium is made immediately available to all members of the Consortium and with other Consortia with whom we have a reciprocal sharing arrangement. Data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) (accession no. GSE116622). Data will be released upon acceptance.

The following data sets were generated

Article and author information

Author details

  1. Erin G Conlon

    Department of Biological Sciences, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  2. Delphine Fagegaltier

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  3. Phaedra Agius

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  4. Julia Davis-Porada

    Department of Biological Sciences, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  5. James Gregory

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  6. Isabel Hubbard

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  7. Kristy Kang

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  8. Duyang Kim

    Center for Genomics of Neurodegenerative disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  9. The New York Genome Center ALS Consortium

  10. Hemali Phatnani

    Center for Genomics of Neurodegenerative Disease, New York Genome Center, New York, United States
    Competing interests
    No competing interests declared.
  11. Neil A Shneider

    Department of Neurology, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3223-7366
  12. James L Manley

    Department of Biological Sciences, Columbia University, New York, United States
    For correspondence
    jlm2@columbia.edu
    Competing interests
    James L Manley, Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8341-1459

Funding

NIH Office of the Director (R35 GM 118136)

  • James L Manley

NIH Office of the Director (5T32GM008798)

  • Erin G Conlon

ALS Association (15-LGCA-234)

  • Hemali Phatnani

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Human post-mortem brain samples were donated for research purposes by next of kin.

Copyright

© 2018, Conlon et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,660
    views
  • 1,216
    downloads
  • 50
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Erin G Conlon
  2. Delphine Fagegaltier
  3. Phaedra Agius
  4. Julia Davis-Porada
  5. James Gregory
  6. Isabel Hubbard
  7. Kristy Kang
  8. Duyang Kim
  9. The New York Genome Center ALS Consortium
  10. Hemali Phatnani
  11. Neil A Shneider
  12. James L Manley
(2018)
Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism
eLife 7:e37754.
https://doi.org/10.7554/eLife.37754

Share this article

https://doi.org/10.7554/eLife.37754

Further reading

    1. Biochemistry and Chemical Biology
    Aaron D Gitler, John D Fryer
    Insight

    New analyses shift the view that some forms of amyotrophic lateral sclerosis and frontotemporal dementia are due to defects in a single RNA-binding protein.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Kira Breunig, Xuifen Lei ... Luiz O Penalva
    Research Article

    RNA binding proteins (RBPs) containing intrinsically disordered regions (IDRs) are present in diverse molecular complexes where they function as dynamic regulators. Their characteristics promote liquid-liquid phase separation (LLPS) and the formation of membraneless organelles such as stress granules and nucleoli. IDR-RBPs are particularly relevant in the nervous system and their dysfunction is associated with neurodegenerative diseases and brain tumor development. Serpine1 mRNA-binding protein 1 (SERBP1) is a unique member of this group, being mostly disordered and lacking canonical RNA-binding domains. We defined SERBP1’s interactome, uncovered novel roles in splicing, cell division and ribosomal biogenesis, and showed its participation in pathological stress granules and Tau aggregates in Alzheimer’s brains. SERBP1 preferentially interacts with other G-quadruplex (G4) binders, implicated in different stages of gene expression, suggesting that G4 binding is a critical component of SERBP1 function in different settings. Similarly, we identified important associations between SERBP1 and PARP1/polyADP-ribosylation (PARylation). SERBP1 interacts with PARP1 and its associated factors and influences PARylation. Moreover, protein complexes in which SERBP1 participates contain mostly PARylated proteins and PAR binders. Based on these results, we propose a feedback regulatory model in which SERBP1 influences PARP1 function and PARylation, while PARylation modulates SERBP1 functions and participation in regulatory complexes.